Country: Singapura
Bahasa: Inggeris
Sumber: HSA (Health Sciences Authority)
CAPECITABINE
DKSH SINGAPORE PTE. LTD.
L01BC06
150 mg
TABLET, FILM COATED
CAPECITABINE 150 mg
ORAL
Prescription Only
F HOFFMANN-LA ROCHE LTD (Primary and Secondary Packager)
ACTIVE
1999-01-20
1 XELODA ® Capecitabine 1. DESCRIPTION 1.1 THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG Cytostatic agent 1.2 TYPE OF DOSAGE FORM Tablets 150 mg and 500 mg. 1.3 ROUTE OF ADMINISTRATION Oral 1.4 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient: capecitabine 2. CLINICAL PARTICULARS 2.1 THERAPEUTIC INDICATION(S) _Breast Cancer: _ Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of a taxane and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. _Colorectal cancer: _ Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer. Xeloda is indicated for the treatment of metastatic colorectal carcinoma. _Gastric Cancer _ Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. 2.2 DOSAGE AND ADMINISTRATION STANDARD DOSAGE Xeloda should only be prescribed by a qualified physician experienced in the utilisation of anti-neoplastic agents. Xeloda tablets should be swallowed with water within 30 minutes after a meal. Treatment should be discontinued if progressive disease or intolerable toxicity is observed. Standard and reduced dose calculations according to body surface area for starting doses of Xeloda of 1250 mg/m 2 and 1000 mg/m 2 are provided in tables 1 and 2, respectively. _Monotherapy: _ _Colon, colorectal and breast Baca dokumen lengkap
TAB-XEL-2023 05 XELODA ® Capecitabine 1. DESCRIPTION 1.1. THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG Cytostatic agent ATC code: L01BC06 1.2. TYPE OF DOSAGE FORM Tablets 150 mg and 500 mg. Tablets 150 mg: Light peach, biconvex and oblong-shaped film-coated tablets containing 150 mg capecitabine. The tablets are engraved "XELODA" on one side and "150" on the other side. Tablets 500 mg: Peach, biconvex, and oblong-shaped film-coated tablets containing 500 mg capecitabine. The tablets are engraved “XELODA” on one side and “500” on the other 1.3. ROUTE OF ADMINISTRATION Oral 1.4. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient: capecitabine One 150 mg tablet contains 150 mg capecitabine. One 500 mg tablet contains 500 mg capecitabine 2. CLINICAL PARTICULARS 2.1. THERAPEUTIC INDICATION(S) _Breast Cancer:_ Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of a taxane and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. _Colorectal cancer:_ Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer. Xeloda is indicated for the treatment of metastatic colorectal carcinoma. _Gastric Cancer_ Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. 2.2. DOSAGE AND ADMINISTRATION STANDARD DOSAGE Xeloda should only be prescribed by a qualified physician experienced in the utilisation of anti-neoplastic agents. Xeloda tablets should be swallowed whole with water within 30 minutes after a meal. Xeloda tablets should not be crushed or cut. If patients cannot swallow Xeloda tablets whole and tablets must be crushed or cut, this Baca dokumen lengkap